Jiřı́ Mayer

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

Medicine, Oncology, Pharmacotherapy +10

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong et al. · The Lancet Oncology · 2011 · 1.6K citations

Medicine, Hematology, Pharmacotherapy +13

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Verena Hoffmann, Michele Baccarani, Joerg Hasford et al. · Leukemia · 2015 · 255 citations · Full text

Medicine, Hematology, Internal Medicine +9

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

Thorsten Zenz, Dominik Vollmer, Martin Trbušek et al. · Leukemia · 2010 · 164 citations

Medicine, Molecular Genetics, Oncology +16